Boehringer Ingelheim Vetmedica Gmbh

Basf Aktiengesellschaft

Other

American Cyanamid Company

Basf Corporation

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Michael Aven

Janine Lamar

Balazs Albrecht

Benjamin Franzmann

Ingo Lang

Tim Lukas

Herbert Wachtel

Henry Van Tuyl Cotter

Guido Endert

Horst Wergen

Matthias Hausmann

Marcus Rainer Knell

Alexander Christ

Steffen Schuy

Ewald Gerhard Sieverding

Andree Jung

Marcus Rainer Rahmel

Holger Reinecke

Leslie May

Henry Van Cotter

Astrid Brandt

Norbert Nelgen

Friedrich Schmidt

Masatoshi Motoyoshi

Hideaki Hasui

Stefen Schuy

Marcus Knell

A preserved liquid aqueous pharmaceutical composition includes one or more etherified cyclodextrin derivatives, at least one water-soluble preservative, and at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble. The liquid aqueous pharmaceutical composition provides an acceptable solubility of the pharmaceutically active compound, such as pimobendan, in aqueous solution whereby the water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivatives allowing the use in an oral administration form.

Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition

The disclosure relates to the field of medicine, in particular to the field of veterinary medicine. The disclosure relates to a pharmaceutical (medicament) formulation of glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof.

Pharmaceutical formulation comprising ciclesonide

An inhaler, preferably for insertion into a nostril, in particular a horse's nostril, with a pressure generator, which has a tensioning device for the drive, and with a tensioning mechanism for tensioning the tensioning device, whereby the tensioning mechanism has a lever gear for tensioning the tensioning device.

Inhaler

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to a pharmaceutical (medicament) formulation of glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof.

The disclosure relates to the field of medicine, in particular to the field of veterinary medicine. The disclosure specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.

Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

A container for holding, dispensing and/or storing a preferably liquid medicament preparation is proposed, which comprises an inner space for the medicament preparation and an at least partially multi-layered wall structure defining the inner space, the wall structure comprising a first layer with a first through-opening of less than 40 &#x3bc;m. Alternatively or additionally, the wall structure comprises a second and third layer, a second through-opening being provided in the second layer and the third layer covering or closing off the wall structure.

Container for an inhaler

Methods of treating airway diseases in equines include administering to an equine an effective amount of ciclesonide or a pharmaceutically acceptable salt thereof or a composition including ciclesonide or a pharmaceutically acceptable salt thereof.

Ciclesonide for the treatment of airway disease in horses

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).

The present invention is directed to a preserved liquid aqueous pharmaceutical composition comprising one or more etherified cyclodextrin derivatives; one or more water-soluble preservatives; preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; benzethonium chloride; cetylpyridinium chloride; sodium metabisulfite; sodium acetate; parabenes and salts thereof, preferably methylparabene, ethylparabene, propylparabene, butylparabene, butylparabene sodium; or combinations thereof; and at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble. The liquid aqueous pharmaceutical composition provides an acceptable solubility of the pharmaceutically active compound, such as pimobendan, in aqueous solution whereby the water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivatives allowing the use in an oral administration form.

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).

Adjuvants selectes from mon/ionic water/soluble mixed polyalkoxy-lated aliphatic alcohol surfactants, non ionic water soluble ethoxylated aliphatic alcohol surfactants, amine ethoxylates, and micronized polymeric waxes enhance the efficacy of fungicidal triazolopzrimidines of structural formula I. They can be incorporated into formulations of the fungicidal compounds or be added to spray mixtures (tank mix) as separately formualted additives in order to improve the efficacy and spectrum of these fungicides. This invention also provides fungicidal compositions of said triazolopzrimidines and adjuvants, as well as methods for their use in the control of photopathogenic fungi 

Growing community of inventors

Mainz, Germany

Michael Aven